CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Corbus Pharmaceuticals Holdings, Inc. - CRBP CFD

    6.324
    2.01%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.572
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Corbus Pharmaceuticals Holdings Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 6.454
    Open* 6.454
    1-Year Change* 3369.89%
    Day's Range* 6.164 - 6.674
    52 wk Range 2.11-13.17
    Average Volume (10 days) 11.97K
    Average Volume (3 months) 307.83K
    Market Cap 31.23M
    P/E Ratio -100.00K
    Shares Outstanding 4.42M
    Revenue N/A
    EPS -11.02
    Dividend (Yield %) N/A
    Beta 2.29
    Next Earnings Date Nov 6, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 20, 2023 6.454 0.080 1.26% 6.374 6.704 6.374
    Sep 19, 2023 6.594 -0.210 -3.09% 6.804 7.044 6.594
    Sep 18, 2023 6.804 0.210 3.18% 6.594 7.054 6.374
    Sep 15, 2023 6.944 0.360 5.47% 6.584 6.954 6.414
    Sep 14, 2023 6.734 0.150 2.28% 6.584 6.844 6.454
    Sep 13, 2023 6.474 -0.130 -1.97% 6.604 6.884 6.394
    Sep 12, 2023 6.454 0.000 0.00% 6.454 6.884 6.454
    Sep 11, 2023 6.464 0.080 1.25% 6.384 6.884 6.274
    Sep 8, 2023 6.434 -0.130 -1.98% 6.564 6.934 6.344
    Sep 7, 2023 6.704 0.210 3.23% 6.494 6.984 6.234
    Sep 6, 2023 6.444 0.220 3.53% 6.224 6.854 6.224
    Sep 5, 2023 6.384 -0.040 -0.62% 6.424 6.584 6.384
    Sep 1, 2023 6.444 -0.510 -7.33% 6.954 6.994 6.444
    Aug 31, 2023 6.624 -0.130 -1.92% 6.754 7.244 6.224
    Aug 30, 2023 6.674 -0.220 -3.19% 6.894 6.944 6.594
    Aug 29, 2023 6.674 0.170 2.61% 6.504 6.974 6.504
    Aug 28, 2023 6.704 0.270 4.20% 6.434 6.984 6.224
    Aug 25, 2023 6.314 0.140 2.27% 6.174 6.664 6.174
    Aug 24, 2023 6.214 0.070 1.14% 6.144 6.634 6.144
    Aug 23, 2023 6.194 0.110 1.81% 6.084 6.584 6.084

    Corbus Pharmaceuticals Holdings, Inc. Events

    Time (UTC) Country Event
    Monday, November 6, 2023

    Time (UTC)

    13:05

    Country

    US

    Event

    Q3 2023 Corbus Pharmaceuticals Holdings Inc Earnings Release
    Q3 2023 Corbus Pharmaceuticals Holdings Inc Earnings Release

    Forecast

    -

    Previous

    -
    Tuesday, March 5, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Corbus Pharmaceuticals Holdings Inc Earnings Release
    Q4 2023 Corbus Pharmaceuticals Holdings Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0.88171 3.93723 36.1436 4.82227
    Revenue 0 0.88171 3.93723 36.1436 4.82227
    Total Operating Expense 39.8354 56.8707 126.747 113.248 61.57
    Selling/General/Admin. Expenses, Total 18.6986 20.4254 28.4802 23.6434 12.956
    Research & Development 16.1368 36.4453 98.2672 89.6048 48.614
    Operating Income -39.8354 -55.989 -122.81 -77.1046 -56.7477
    Interest Income (Expense), Net Non-Operating -2.46268 -1.5514 -1.72936 1.06902 1.07557
    Net Income Before Taxes -42.3469 -45.6404 -111.269 -71.4537 -55.6721
    Net Income After Taxes -42.3469 -45.6404 -111.269 -71.4537 -55.6721
    Net Income Before Extra. Items -42.3469 -45.6404 -111.269 -71.4537 -55.6721
    Net Income -42.3469 -45.6404 -111.269 -71.4537 -55.6721
    Income Available to Common Excl. Extra. Items -42.3469 -45.6404 -111.269 -71.4537 -55.6721
    Income Available to Common Incl. Extra. Items -42.3469 -45.6404 -111.269 -71.4537 -55.6721
    Diluted Net Income -42.3469 -45.6404 -111.269 -71.4537 -55.6721
    Diluted Weighted Average Shares 4.17068 4.09967 2.60444 2.12976 1.8998
    Diluted EPS Excluding Extraordinary Items -10.1535 -11.1327 -42.7229 -33.5501 -29.3042
    Diluted Normalized EPS -8.95464 -10.9849 -42.7229 -33.5501 -29.3042
    Total Extraordinary Items
    Other, Net -0.04877 11.9 13.2702 4.58184
    Unusual Expense (Income) 5
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0 0
    Total Operating Expense 8.18899 17.297 10.7968 8.18146 12.34
    Selling/General/Admin. Expenses, Total 3.94029 3.90868 4.55406 4.07327 4.84037
    Research & Development 4.24871 13.3883 6.24276 4.10819 2.49964
    Operating Income -8.18899 -17.297 -10.7968 -8.18146 -12.34
    Interest Income (Expense), Net Non-Operating -0.77751 -0.67729 -0.35778 -0.67798 -0.7002
    Other, Net 0.18266 0.22951 0.27555 0.07771 -0.20868
    Net Income Before Taxes -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
    Net Income After Taxes -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
    Net Income Before Extra. Items -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
    Net Income -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
    Income Available to Common Excl. Extra. Items -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
    Income Available to Common Incl. Extra. Items -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
    Diluted Net Income -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
    Diluted Weighted Average Shares 4.2777 4.18156 4.15711 4.17561 4.1752
    Diluted EPS Excluding Extraordinary Items -2.0534 -4.24359 -2.61698 -2.1031 -3.17324
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -2.0534 -4.24359 -2.61698 -2.1031 -1.97569
    Unusual Expense (Income) 0 0 0 5
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 60.1811 100.205 92.0746 38.1547 44.2403
    Cash and Short Term Investments 59.197 97.6471 85.4334 31.7487 41.7485
    Cash 3.80516 6.75159 1.82578 0.88412 0.80894
    Cash & Equivalents 13.1976 18.255 83.6077 30.8646 40.9395
    Total Receivables, Net 0 2.57833 2.68107
    Prepaid Expenses 0.79162 2.36501 3.71286 3.72493 2.49184
    Other Current Assets, Total 0.19248 0.19248 0.35 0
    Total Assets 66.3119 107.73 102.295 49.1425 46.9893
    Property/Plant/Equipment, Total - Net 5.49807 7.00181 9.31636 10.9029 2.70521
    Property/Plant/Equipment, Total - Gross 8.59129 9.37405 11.6652 12.3088 3.37179
    Accumulated Depreciation, Total -3.09322 -2.37224 -2.34884 -1.40596 -0.66658
    Other Long Term Assets, Total 0.63277 0.52381 0.90394 0.08497 0.04382
    Total Current Liabilities 12.6399 17.0075 31.8978 34.8877 18.0893
    Accounts Payable 2.17396 1.78228 7.38118 11.0914 6.34534
    Accrued Expenses 7.28012 11.2303 23.0095 23.0437 9.85119
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 3.14899 3.86128 0.71016 0.75266 0.39431
    Other Current Liabilities, Total 0.03687 0.13371 0.797 0 1.4985
    Total Liabilities 33.3219 38.6222 57.02 42.9849 19.4652
    Total Long Term Debt 15.9844 15.6363 18.029 0 0
    Other Liabilities, Total 4.69756 5.97842 7.09317 8.09723 1.37589
    Total Equity 32.99 69.108 45.2749 6.15757 27.5241
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Common Stock 0.00042 0.01252 0.00989 0.00647 0.00573
    Additional Paid-In Capital 425.196 418.892 349.358 198.975 148.889
    Retained Earnings (Accumulated Deficit) -392.081 -349.734 -304.093 -192.824 -121.37
    Total Liabilities & Shareholders’ Equity 66.3119 107.73 102.295 49.1425 46.9893
    Total Common Shares Outstanding 4.1713 4.17395 3.29476 2.15555 1.90806
    Accounts Receivable - Trade, Net 0 1.6183 2.68107
    Long Term Debt 15.9844 15.6363 18.029
    Short Term Investments 42.1943 72.6405
    Other Equity, Total -0.12609 -0.06245
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 45.865 60.1811 67.3478 75.238 88.4756
    Cash and Short Term Investments 44.227 59.197 66.2292 73.3032 86.1212
    Cash 2.89716 3.80516 3.80611 3.98804 12.9421
    Cash & Equivalents 4.42728 13.1976 8.63754 21.7826 44.0842
    Short Term Investments 36.9026 42.1943 53.7856 47.5326 29.0949
    Total Receivables, Net
    Accounts Receivable - Trade, Net
    Prepaid Expenses 1.44552 0.79162 0.92616 1.74227 2.16186
    Other Current Assets, Total 0.19248 0.19248 0.19248 0.19248 0.19248
    Total Assets 51.6453 66.3119 73.8306 82.0666 95.6751
    Property/Plant/Equipment, Total - Net 5.12041 5.49807 5.87229 6.24708 6.6468
    Property/Plant/Equipment, Total - Gross 8.39551 8.59129 8.78111 8.96512 9.21476
    Accumulated Depreciation, Total -3.27509 -3.09322 -2.90883 -2.71803 -2.56796
    Other Long Term Assets, Total 0.65986 0.63277 0.61048 0.58159 0.5527
    Total Current Liabilities 14.3589 12.6399 17.4692 15.6298 15.1177
    Accounts Payable 1.32299 2.17396 1.37422 1.98662 2.69681
    Accrued Expenses 7.78697 7.28012 6.07764 5.92389 6.66826
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 5.21212 3.14899 9.88364 7.58555 5.61892
    Other Current Liabilities, Total 0.03687 0.03687 0.13371 0.13371 0.13371
    Total Liabilities 35.1863 33.3219 31.8845 32.5968 34.5198
    Total Long Term Debt 13.9724 15.9844 9.38585 11.6122 13.7284
    Long Term Debt 13.9724 15.9844 9.38585 11.6122 13.7284
    Other Liabilities, Total 6.85501 4.69756 5.02944 5.35477 5.67369
    Total Equity 16.459 32.99 41.9461 49.4699 61.1553
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Common Stock 0.00042 0.00042 0.01253 0.01253 0.01253
    Additional Paid-In Capital 426.352 425.196 423.342 421.997 420.483
    Retained Earnings (Accumulated Deficit) -409.825 -392.081 -381.202 -372.42 -359.171
    Other Equity, Total -0.06847 -0.12609 -0.20687 -0.11932 -0.16969
    Total Liabilities & Shareholders’ Equity 51.6453 66.3119 73.8306 82.0666 95.6751
    Total Common Shares Outstanding 4.21513 4.1713 4.17561 4.1752 4.17478
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -42.3469 -45.6404 -111.269 -71.4537 -55.6721
    Cash From Operating Activities -37.5444 -48.1837 -99.6857 -45.7207 -30.0673
    Cash From Operating Activities 0.763 0.99982 1.12385 0.73938 0.49394
    Non-Cash Items 8.06298 12.1534 13.6647 12.5179 8.10229
    Cash Interest Paid 1.96958 1.74088 0.62915 0.02945 0.01044
    Changes in Working Capital -4.02351 -15.6965 -3.20492 12.4757 17.0086
    Cash From Investing Activities 30.0741 -73.4165 -0.48449 -2.74254 -2.30042
    Capital Expenditures -0.01345 -0.05417 -0.48449 -2.74254 -2.30042
    Cash From Financing Activities -0.53362 60.8234 154.875 38.4635 11.4197
    Financing Cash Flow Items 0 -1.82044 -6.03942 -2.57155 -0.69018
    Issuance (Retirement) of Stock, Net 0 62.5861 142.201 40.6771 12.0527
    Issuance (Retirement) of Debt, Net -0.53362 0.05778 18.7135 0.35798 0.05719
    Net Change in Cash -8.00392 -60.7768 54.7047 -9.99978 -20.948
    Other Investing Cash Flow Items, Total 30.0876 -73.3624
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -17.7448 -42.3469 -31.4678 -22.6861 -9.43724
    Cash From Operating Activities -15.115 -37.5444 -30.0895 -22.8444 -10.6153
    Cash From Operating Activities 0.18187 0.763 0.5786 0.3878 0.19572
    Non-Cash Items 1.22002 8.06298 6.78652 5.24585 2.75334
    Cash Interest Paid 0.64146 1.96958 1.40721 0.88743 0.431
    Changes in Working Capital 1.22795 -4.02351 -5.98672 -5.79193 -4.12716
    Cash From Investing Activities 5.5497 30.0741 18.2944 24.2657 42.9622
    Capital Expenditures 0 -0.01345 -0.01345 -0.01345 -0.01345
    Other Investing Cash Flow Items, Total 5.5497 30.0876 18.3078 24.2791 42.9756
    Cash From Financing Activities -0.11301 -0.53362 -0.76794 -0.65723 -0.32713
    Financing Cash Flow Items 0 0 0 0
    Issuance (Retirement) of Stock, Net 0.03706 0 0 0 0
    Issuance (Retirement) of Debt, Net -0.15007 -0.53362 -0.76794 -0.65723 -0.32713
    Net Change in Cash -9.67828 -8.00392 -12.563 0.76403 32.0197
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Ikarian Capital LLC Hedge Fund 4.3462 192260 0 2023-06-30 HIGH
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.0567 179456 1 2023-06-30 LOW
    Sio Capital Management, LLC Hedge Fund 3.3908 150000 0 2023-06-30 HIGH
    BlackRock Institutional Trust Company, N.A. Investment Advisor 1.7993 79597 9069 2023-06-30 LOW
    Boothbay Fund Management, LLC Investment Advisor/Hedge Fund 0.8585 37976 0 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7429 32865 0 2023-06-30 LOW
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.7143 31600 17919 2023-06-30 LOW
    Andbank Wealth Management, SGIIC, S.A.U. Investment Advisor 0.5047 22328 22328 2023-03-31 MED
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.2979 13179 0 2023-06-30 LOW
    Moran (Sean F) Individual Investor 0.1501 6642 -1 2023-03-24 LOW
    Tekla Capital Management LLC Investment Advisor 0.1163 5143 0 2023-06-30 LOW
    Fidelity Management & Research Company LLC Investment Advisor 0.0758 3353 -12 2023-06-30 LOW
    Cohen (Yuval) Individual Investor 0.074 3274 -1 2023-03-24 LOW
    Morgan Stanley & Co. LLC Research Firm 0.0716 3168 -319 2023-06-30 MED
    Dorsey, Wright & Associates, LLC Investment Advisor/Hedge Fund 0.0578 2555 2555 2023-06-30 HIGH
    Group One Trading, L.P. Research Firm 0.0462 2045 -220 2023-06-30 HIGH
    T. Rowe Price Associates, Inc. Investment Advisor 0.0424 1876 0 2023-06-30 LOW
    BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.0368 1629 0 2023-06-30 LOW
    Catlin (Avery W) Individual Investor 0.0354 1567 0 2023-03-24
    RBC Capital Partners Investment Advisor 0.0342 1512 1512 2023-06-30 HIGH

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Corbus Pharmaceuticals Company profile

    Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. The company was founded in 2009 and is based in Norwood, Massachusetts.
    Industry: Bio Therapeutic Drugs

    500 River Ridge Drive
    NORWOOD
    MASSACHUSETTS 02062
    US

    Income Statement

    • Annual
    • Quarterly

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    US100

    14,682.60 Price
    -1.830% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    XRP/USD

    0.51 Price
    -2.100% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Oil - Crude

    89.44 Price
    +0.350% 1D Chg, %
    Long position overnight fee 0.0355%
    Short position overnight fee -0.0574%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    ETH/USD

    1,591.29 Price
    -2.380% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading